Cardiac Science to Purchase R & D Company

Irvine biomedical company Cardiac Science Inc. said Thursday it agreed to acquire HeartSine Technologies Inc., a privately held research and development firm with operations in Northern Ireland and Orange County, in a stock transaction.

HeartSine’s expertise and defibrillation technology will enable Cardiac Science to bring new products to market that offer cardiac arrest victims life-saving defibrillation therapy without human intervention, Cardiac said.

HeartSine will receive 1 million shares of stock. Cardiac’s shares were trading recently at about $2, making the value of the stock about $2 million.

The transaction is scheduled to close in about 30 days.